MARCH8 displayed the prevalent CNV amplification in most cancers like ovarian serous cystadenocarcinoma (OV) and bladder urothelial carcinoma (BLCA) (The cancer names and their abbreviations were referenced from TCGA database listed in Table S1). Here, MARCHF8 is linked to ovarian serous cystadenocarcinoma.